Your browser doesn't support javascript.
loading
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China.
Xu, Binghe; Li, Huiping; Jiang, Zefei; Gu, Lin; Tang, Jinhai; Xie, Hui; Pan, Yueyin; Liu, Yunjiang; Cui, Shude; Wang, Xiaojia; Cai, Li; Zhang, Yiqiong; Zhao, Huadong; Shao, Zhimin.
  • Xu B; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Li H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Jiang Z; Department of Breast Cancer, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.
  • Gu L; Department of Breast Cancer, Tianjin Cancer Institute and Hospital, Tianjin 300060, China.
  • Tang J; Department of Breast Cancer, Jiangsu Provincial Hospital, Nanjing 210029, China.
  • Xie H; Department of Breast Cancer, Jiangsu Provincial Hospital, Nanjing 210029, China.
  • Pan Y; Department of Breast Cancer, the First Affiliated Hospital of China University of Science and Technology, Hefei 230001, China.
  • Liu Y; Department of Breast Cancer, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
  • Cui S; Department of Breast Cancer, Henan Cancer Hospital, Zhengzhou 450008, China.
  • Wang X; Department of Breast Cancer, Zhejiang Cancer Hospital, Hangzhou 310012, China.
  • Cai L; Department of Breast Cancer, Harbin Medical University Cancer Hospital, Harbin 150081, China.
  • Zhang Y; Department of Clinical Development, Pfizer (China) R&D Co. Ltd, Shanghai 201203, China.
  • Zhao H; Department of Statistics, Pfizer (China) R&D Co. Ltd, Shanghai 201203, China.
  • Shao Z; Department of Breast Surgery, Shanghai Cancer Center/Cancer Institute, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Chin J Cancer Res ; 34(6): 592-600, 2022 Dec 30.
Article en En | MEDLINE | ID: mdl-36714346
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article